Details for: LOVENOX
Company: SANOFI-AVENTIS CANADA INC
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02012472 | LOVENOX | ENOXAPARIN SODIUM | 30 MG / 0.3 ML | SOLUTION | SUBCUTANEOUS |
| 02236883 | LOVENOX | ENOXAPARIN SODIUM | 40 MG / 0.4 ML | SOLUTION | SUBCUTANEOUS |
| 02378426 | LOVENOX | ENOXAPARIN SODIUM | 60 MG / 0.6 ML | SOLUTION | SUBCUTANEOUS |
| 02378434 | LOVENOX | ENOXAPARIN SODIUM | 80 MG / 0.8 ML | SOLUTION | SUBCUTANEOUS |
| 02236564 | LOVENOX WITH PRESERVATIVE 300MG/3ML | ENOXAPARIN SODIUM | 100 MG / ML | SOLUTION | INTRAVENOUS |
| 02378442 | LOVENOX | ENOXAPARIN SODIUM | 100 MG / ML | SOLUTION | SUBCUTANEOUS |
| 02236564 | LOVENOX WITH PRESERVATIVE 300MG/3ML | ENOXAPARIN SODIUM | 100 MG / ML | SOLUTION | SUBCUTANEOUS |
Summary Reports
Regulatory Decision Summary
Summary Safety Review - Low-Molecular-Weight Heparins - Assessing the potential risk of bleeding in or around the spinal cord (Spinal/Epidural Hematoma)
Summary Safety Review - Low-Molecular-Weight Heparins - Assessing the potential risk of bleeding in or around the spinal cord (Spinal/Epidural Hematoma)
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.